Home>>Analytical Standards>>C18 Galactosylceramide-d35 (d18:1/18:0-d35)

C18 Galactosylceramide-d35 (d18:1/18:0-d35) (Synonyms: Galactosylceramide (d18:1/18:0-d35), GalCer(d18:1/18:0-d35), N-octadecanoyl Psychosine-d35)

Catalog No.GC46990

An internal standard for the quantification of C18 galactosylceramide

Products are for research use only. Not for human use. We do not sell to patients.

C18 Galactosylceramide-d35 (d18:1/18:0-d35) Chemical Structure

Cas No.: 145176-92-7

Size Price Stock Qty
5 mg
$720.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

C18 Galactosylceramide-d35 is intended for use as an internal standard for the quantification of C18 galactosylceramide by GC- or LC-MS. C18 Galactosylceramide is a naturally occurring sphingolipid that has been found in the cerebellum of rats and humans.1,2 It is selectively localized with cholesterol over potassium, sodium, or phosphocholine in rat cerebellum white matter.1 [Matreya, LLC. Catalog No. 1914]

1.BÖrner, K., Nygren, H., Hagenhoff, B., et al.Distribution of cholesterol and galactosylceramide in rat cerebellar white matterBiochem. Biophys. Acta.1761(3)335-344(2006) 2.Boutin, M., Sun, Y., Shacka, J.J., et al.Tandem mass spectrometry multiplex analysis of glucosylceramide and galactosylceramide isoforms in brain tissues at different stages of Parkinson DiseaseAnal. Chem.88(3)1856-1863(2016)

Reviews

Review for C18 Galactosylceramide-d35 (d18:1/18:0-d35)

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for C18 Galactosylceramide-d35 (d18:1/18:0-d35)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.